期刊文献+

老年晚期结直肠癌患者在替吉奥基础上联合早期姑息治疗的临床效果及对生活质量的影响 被引量:1

全文增补中
导出
摘要 目的:探究老年晚期结直肠癌患者在替吉奥基础上联合早期姑息治的临床治疗效果。方法:选取我院2016年1月~2017年1月收治的78例老年晚期结直肠癌患者为研究对象,按照临床治疗方式不同将所有研究对象在遵循患者以及患者家属意愿的情况下随机均分为对照组和实验组,对照组38例患者给予替吉奥治疗,实验组在对照组临床治疗的基础上联合早期姑息治疗,两周后比较两组患者临床治疗效果,患者治疗前后生活质量变化。结果:实验组患者临床治疗总有效率明显高于对照组(94.8%vs81.6%),两组患者治疗后生活质量评分(QIL)均有一定程度的提高,其中实验组患者治疗后生活质量评分(QIL)增幅明显大于对照组两组患者各项数据具有明显统计学意义(P<0.05).结论:对于老年晚期结直肠癌患者在替吉奥基础上联合早期姑息治疗能有效提高患者临床治疗效果,提高患者生活质量,增进医患之间的合作关系,提高患者对临床治疗的认同感和满意率。 Objective: To explore the clinical effect of the treatment of elderly patients with advanced colorectal cancer in S-1 based on combined with early palliative treatment. Methods: in our hospital from January 2016 ~2017 year in January 78 cases of elderly patients with advanced colorectal cancer patients as the research object, according to the different ways of clinical treatment of all participants in the study were to follow the wishes of the situation as well as family members of patients were randomly divided into control group and experimental group, 38 patients in control group were treated with S-1 treatment, experimental group on the basis of the control clinical treatment combined with early palliative treatment, two weeks after the two groups of patients with clinical curative effect, changes in the quality of life of patients before and after treatment. Results: the clinical total effective rate of experimental group was significantly higher than the control group(94.8%vs81.6%), quality of life score after treatment in two groups(QIL) were improved to a certain extent, the treatment of patients in the experimental group after the quality of life score(QIL) was significantly greater than that of the control group was statistically significant in two groups of the data(P<0.05) conclusion: for elderly patients with advanced colorectal cancer in S-1 based on joint early palliative care can effectively improve the clinical treatment effect, improve the quality of life of patients, improve doctor-patient relationship, improve patient identification for clinical treatment and satisfaction rate.
作者 尤江莲
出处 《中国妇幼健康研究》 2017年第S2期12-13,共2页 Chinese Journal of Woman and Child Health Research
关键词 老年晚期结直肠癌 替吉奥 早期姑息治疗 elderly patients with advanced colorectal cancer S-1 early palliative treatment
  • 相关文献

二级参考文献60

  • 1杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4(2):85-90. 被引量:1571
  • 2Richard M G,Neal J M,Josep Tabernero,et al.Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer[J].Gastrointest Cancer,2009,3(suppl 2):S23-S27.
  • 3Hanna K S,Richard M G.Colorectal cancer treatment in older patients[J].Gastrointestinal cancer research,2007,1:248-253.
  • 4Underhill C,Goldstein D,Gorbounova VA,et al.A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer[J].Oncology.2007,73(1-2):9-20.
  • 5Atkins JN,Jacobs SA,Wieand HS,et al.Pemetrexed/oxaliplatin for first-line treatment of patients with advanced colorectal cancer:a phase II trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research Program[J].Clin Colorectal Cancer.2005 Sep,5(3):181-187.
  • 6John W,Picus J,Blanke CD,et al.Activity of multitargeted antifolate (pemetrexed disodium,LY231514) in patients with advanced colorectal carcinoma:results from a phase II study[J].Cancer.2000 Apr 15;88(8):1807-1813.
  • 7Hochster H,Kettner E,Kroning H,et al.Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer[J].Clin Colorectal Cancer.2005 Nov;5(4):257-562.
  • 8Souglakos J,Androulakis N,Syrigos K,et al.FOLFOXIRI(folinic acid,5-fluorouracil,oxaliplatin and irinotecan) VS FOLFIRI (foiinic acid,5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC):a multicentre andomised phase Ⅲtrial from the Hellenic Oncology Research Group (HORG)[J].Br J Cancer,2006,94 (6):798-805.
  • 9VareyAH,Rennel ES,Qiu Y,et al.VEGF 165 b,an antiangiogenic VEGF2A isoform,binds and inhibits bevacizumab treatment in experimental colorectal carcinoma:balance of pro-and antiangiogenic VEGF2A isoforms has implications for therapy[J].BrJ Cancer,2008,98:1366-1379.
  • 10van Krieken H,Tol J.Setting future standards for KRAS testing in colorectal cancer[J].Pharmacogenomics,2009,10:1-3.

共引文献39

同被引文献8

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部